Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay

References

• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010;24(Suppl 1):3-14
   PubMed Web of Science ®Google Scholar
• de Boer NK, Löwenberg M, Hoentjen F. Management of Crohn’s disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Miheller P, Kiss LS, Lorinczy K, et al. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use. Expert Opin Biol Ther 2012;12:179-92
   PubMed Web of Science ®Google Scholar
• Adalimumab (Humira, AbbVie Inc.) package insert. Available at: http://www.rxabbvie.com/pdf/humira.pdf [Last accessed 22 July 2015]
   Google Scholar
• Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-58
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9
   PubMed Web of Science ®Google Scholar
• Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013;78-79:39-44
   PubMed Web of Science ®Google Scholar
• BRIDGe Anti-TNF Optimizer. Available at: http://www.bridgeibd.com/anti-tnf-optimizer [Last accessed 1 December 2015]
   Google Scholar
• Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-4
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009;137:1628-40
   PubMed Web of Science ®Google Scholar
• Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn’s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016;65:1126-31
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 2008;28:1122-6
   PubMed Web of Science ®Google Scholar
• Melmed G, Irving P, Jones J, et al. Interpretation of anti-TNF drug concentration and antibody levels in IBD: a mobile app to guide management based on results from a RAND appropriateness panel. Am J Gastroenterol 2014;109(Suppl 2):S511
   PubMed Web of Science ®Google Scholar
• Rubin DT, Mulani P, Chao J, et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn’s disease: results from the CHARM trial. Inflamm Bowel Dis 2012;18:818-25
   PubMed Web of Science ®Google Scholar
• Pukitis A, Zake T, Groma V, et al. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn’s disease: case report and review of the literature. J Gastrointestin Liver Dis 2013;22:333-6
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
   PubMed Web of Science ®Google Scholar
• Iizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease. Gut 2006;55:744-5
   PubMed Web of Science ®Google Scholar
• Bosca MM, Perez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn’s disease: treatment with tumour necrosis factor inhibitor. Gut 2006;55:294-5
   PubMed Web of Science ®Google Scholar
• Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn’s disease treated with infliximab. Inflamm Bowel Dis 2008;14:431-2
   PubMed Web of Science ®Google Scholar
• Iizuka M, Sagara S, Etou T. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn’s disease. Inflamm Bowel Dis 2011;17:E67-8
   PubMedGoogle Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24
   PubMed Web of Science ®Google Scholar
• Plevy S, Silverberg MS, Lockton S, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn’s disease, and ulcerative colitis patients. Inflamm Bowel Dis 2013;19:1139-48
   PubMed Web of Science ®Google Scholar
• Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995;36:724-30
   PubMed Web of Science ®Google Scholar
• Panés J, Granger DN. Leukocyte–endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114:1066-90
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015;41:613-23
   PubMed Web of Science ®Google Scholar